Safety Profile of Opicapone in the Management of Parkinson’s Disease-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Safety Profile of Opicapone in the Management of Parkinson’s Disease

Published:2019-10-11 Issue:4 Volume:9 Page:733-740
ISSN:1877-7171
Container-title:Journal of Parkinson's Disease
language:
Short-container-title:JPD

Author:

Lees Andrew¹,Ferreira Joaquim J.²³,Rocha José-Francisco⁴,Rascol Olivier⁵,Poewe Werner⁶,Gama Helena⁴,Soares-da-Silva Patrício⁴⁷⁸

Affiliation:

1. University College London, Reta Lila Weston Institute, London, UK

2. Instituto de Medicina Molecular, Faculty of Medicine, University of Lisbon, Portugal

3. CNS – Campus Neurológico Sénior, Torres Vedras, Portugal

4. Department of Research and Development, BIAL – Portela & Ca SA, S. Mamede do Coronado, Portugal

5. Department of Clinical Pharmacology and Neurosciences, INSERM and University Hospital of Toulouse, Toulouse, France

6. Department of Neurology, Innsbruck Medical University, Innsbruck, Austria

7. Department of Pharmacology and Therapeutics, Faculty of Medicine, University Porto, Porto, Portugal

8. MedInUP, Center for Drug Discovery and Innovative Medicines, University Porto, Porto, Portugal

Publisher

IOS Press

Subject

Cellular and Molecular Neuroscience,Neurology (clinical)

Reference10 articles.

1. Medicinal chemistry of catechol O-methyltransferase (COMT) inhibitors and their therapeutic utility;Kiss;J Med Chem,2014

2. Opicapone as an adjunct to levodopa in patients with Parkinson’s disease and end-of-dose motor fluctuations: A randomised, double-blind, controlled trial;Ferreira;Lancet Neurol,2016

3. Opicapone as adjunct to levodopa therapy in patients with parkinson disease and motor fluctuations: A randomized clinical trial;Lees;JAMA Neurol,2017

4. Effectiveness of opicapone and switching from entacapone in fluctuating Parkinson disease;Ferreira;Neurology,2018

5. Adverse event reporting in clinical trials in Parkinson’s Disease: Time for change;Olanow;Mov Disord,2018

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-effectiveness Analysis of COMT-inhibitors as Adjuvant Treatments to Levodopa in Patients with Advanced Parkinson's Disease;Clinical Therapeutics;2024-09

2. Levodopa–Entacapone–Carbidopa Intestinal Gel in the Treatment of Advanced Parkinson’s Disease: A Single Center Real-World Experience;Pharmaceutics;2024-03-25

3. Opicapone versus entacapone: Head‐to‐head retrospective data‐based comparison of healthcare resource utilization in people with Parkinson's disease new to catechol‐O‐methyltransferase (COMT) inhibitor treatment;European Journal of Neurology;2023-08-19

4. Off-time Treatment Options for Parkinson’s Disease;Neurology and Therapy;2023-01-12

5. The Potential Role of Voltage-Dependent Anion Channel in the Treatment of Parkinson’s Disease;Oxidative Medicine and Cellular Longevity;2022-10-05

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3